Five Prime Therapeutics Inc. (FPRX)

11.88 +0.31 (+2.679%)

IEX Real-Time Price

November 16, 2018 EST.

Nasdaq Global Select : Healthcare

Prev Close 11.57

Price Open 11.45

Volume: 267,542

Avg Volume: 328,343

Market Cap: 421.33M

P/E Ratio -2.95

52 Wk Range 10.35-27.61



FPRX Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-10-15
34.39M
2.46M
8.33
7.16%

2018-09-28
34.37M
2.49M
7.18
7.26%

2018-09-14
34.37M
2.59M
6.47
7.53%

2018-08-31
34.37M
2.68M
7.83
7.80%




FPRX Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-08-08
Q2 2018
AMC
-1.25 (5)
-0.99
0.26

2018-05-08
Q1 2018
AMC
-0.54 (3)
-0.63
-0.09

2018-05-03
Q1 2018
N/A
-0.54 (3)
0.00
0.00

2018-02-27
Q4 2017
AMC
-1.29 (4)
-1.04
0.25

News

Five Prime Therapeutics Initiates Patient Dosing in a Phase 1 Clinical Trial of FPT155, a First-in-Class CD80 Fusion Protein (2018-11-14 16:05 Business Wire)

Studies in preclinical models suggest FPT155 has the potential to be a potent T-cell co-stimulator with strong monotherapy anti-tumor activity The Phase 1 clinical trial will evaluate FPT155 monotherapy across multiple tumor types Five Prime Therapeutics, Inc .(Nasdaq…

 


Statistics

Shares Outstanding: 35.47M

Top 15 Institution Percent: 98.10

Price To Sales: 6.95

Price To Book: 1.38

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -36.17

Return On Equity: -44.92

Profit Margin: N/A

Price History

Beta: 3.36

50-day Moving Avg: 13.06

200-day Moving Avg: 15.99

YTD Change: -47.18

5-day Change: 5.79

1-month Change: -17.44

3-month Change: -9.86

6-month Change: -37.14

1-year Change: -53.52

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Five Prime Therapeutics Inc.

Exchange: Nasdaq Global Select

Industry: Biotechnology

Sector: Healthcare

Website: http://www.fiveprime.com

Five Prime Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel protein therapeutics to improve lives of patients with serious diseases.